tallózása szerző szerint "László, Viktória"

A találatok rendezése: Rendezés: Találatok:

  • Circulating activin A is a novel prognostic biomarker in malignant pleural mesothelioma - A multi-institutional study 
    Hoda, M Alireza; Dong, Yawen; Rózsás, Anita; Klikovits, Thomas; László, Viktória; Bahil, Ghanim; Paul, Stockhammer; Judit, Ozsvar; Marko, Jakopovic; Miroslav, Samarzija; Luka, Brcic; Mátyás, Bendek; Ildikó, Szirtes; Glen, Reid; Michaela, B Kirschner; Steven, C Kao; Isabelle, Opitz; Walter, Weder; Thomas, Frauenfelder; Thi Dan Linh, Nguyen-Kim; Clemens, Aigner; Walter, Klepetko; Nico, van Zandwijk; Walter, Berger; Döme, Balázs; Michael, Grusch; Hegedűs, Balázs (2016)
    INTRODUCTION: The deregulation of activin expression is often observed in various malignancies. Previous studies indicate that activin A plays a protumourigenic role in malignant pleural mesothelioma (MPM). The aim of the ...
  • Subtype-specific KRAS mutations in advanced lung adenocarcinoma: A retrospective study of patients treated with platinum-based chemotherapy 
    Cserepes, Mihály; Ostoros, Gyula; Lohinai, Zoltán; Rásó, Erzsébet; Barbai, Tamás; Tímár, József; Rózsás, Anita; Moldvay, Judit; Kovalszky, Ilona; Fábián, Katalin; Gyulai, Márton; Ghanim, Bahil; László, Viktória; Thomas, Klikovits; Hoda, Mir Alireza; Grusch, Michael; Berger, Walter; Klepetko, Walter; Hegedűs, Balázs; Döme, Balázs (2014)
    Background: Platinum-based chemotherapy is the most common treatment in advanced-stage lung adenocarcinoma. Because the clinical significance of KRAS mutational status in this setting has not yet been clearly determined, ...
  • Trabectedin is active against malignant pleural mesothelioma cell and xenograft models and synergizes with chemotherapy and bcl-2 inhibition in vitro 
    Hoda, Mir A; Pirker, Christine; Dong, Yawen; Schelch, Karin; Heffeter, Petra; Kushtrim, Kryeziu; Sushilla, van Schoonhoven; Thomas, Klikovits; László, Viktória; Rózsás, Anita; Ozsvár, Judit; Walter, Klepetko; Döme, Balázs; Michael, Grusch; Hegedűs, Balázs; Walter, Berger (2016)
    Malignant pleural mesothelioma (MPM) is characterized by widespread resistance to systemic therapy. Trabectedin is an antineoplastic agent targeting both the malignant cells and the tumor microenvironment which has been ...